Altered natural killer (NK) cell frequency and phenotype in latent autoimmune diabetes in adults (LADA) prior to insulin deficiency.
Approximately 10% of the patients diagnosed with type 2 diabetes (T2D) have detectable serum levels of glutamic acid decarboxylase 65 autoantibodies (GADA). These patients usually progress to insulin dependency within a few years, and are classified as being latent autoimmune diabetes in adults (LADA). A decrease in the frequency of peripheral blood natural killer (NK) cells has been reported recently in recent-onset T1D and in high-risk individuals prior to the clinical onset. As NK cells in LADA patients have been investigated scarcely, the aim of this study was to use multicolour flow cytometry to define possible deficiencies or abnormalities in the frequency or activation state of NK cells in LADA patients prior to insulin dependency. All patients were GADA-positive and metabolically compensated, but none were insulin-dependent at the time blood samples were taken. LADA patients exhibited a significant decrease in NK cell frequency in peripheral blood compared to healthy individuals (P=0.0018), as reported previously for recent-onset T1D patients. Interestingly, NKG2D expression was increased significantly (P<0.0001), whereas killer cell immunoglobulin-like receptor (KIR)3DL1 expression was decreased (P<0.0001) within the NK cell population. These observations highlight a defect in both frequency and activation status of NK cells in LADA patients and suggest that this immunological alteration may contribute to the development of autoimmune diabetes by affecting peripheral tolerance. Indeed, recent evidence has demonstrated a regulatory function for NK cells in autoimmunity. Moreover, the decrease in NK cell number concords with observations obtained in recent-onset T1D, implying that similar immunological dysfunctions may contribute to the progression of both LADA and T1D.
Akesson
C
C
Cellular Autoimmunity Unit, Department of Clinical Sciences, Malmö University Hospital, Malmö, Sweden.
Uvebrant
K
K
Oderup
C
C
Lynch
K
K
Harris
R A
RA
Lernmark
A
A
Agardh
C-D
CD
Cilio
C M
CM
D000328:Adult; D017668:Age of Onset; D000368:Aged; D001323:Autoantibodies / Q000097:blood / Q000276:immunology; D001324:Autoantigens / Q000276:immunology; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000175:diagnosis / Q000276:immunology*; D003924:Diabetes Mellitus, Type 2 / Q000175:diagnosis; D003937:Diagnosis, Differential; D018450:Disease Progression; D005260:Female; D005968:Glutamate Decarboxylase / Q000276:immunology; D006683:HLA-DQ Antigens / Q000032:analysis; D059866:HLA-DQ beta-Chains; D006801:Humans; D007108:Immune Tolerance; D016130:Immunophenotyping; D007328:Insulin / Q000097:blood / Q000276:immunology; D007694:Killer Cells, Natural / Q000276:immunology*; D018655:Lymphocyte Count; D008231:Lymphopenia / Q000209:etiology* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D055655:NK Cell Lectin-Like Receptor Subfamily K / Q000097:blood; D011236:Prediabetic State / Q000097:blood / Q000276:immunology*; D054341:Receptors, KIR3DL1 / Q000097:blood / Q000172:deficiency; D012306:Risk; D016176:T-Lymphocyte Subsets / Q000276:immunology
D001323:Autoantibodies; D001324:Autoantigens; D006683:HLA-DQ Antigens; D059866:HLA-DQ beta-Chains; C069051:HLA-DQB1 antigen; D007328:Insulin; C515083:KIR3DL1 protein, human; C527085:KLRK1 protein, human; D055655:NK Cell Lectin-Like Receptor Subfamily K; D054341:Receptors, KIR3DL1; D005968:Glutamate Decarboxylase; C401141:glutamate decarboxylase 2
Adv Immunol. 2008;100:1-12
19111161
Nature. 1995 Nov 16;378(6554):245-8
7477341
Diabetes. 1993 Feb;42(2):359-62
8425674
J Exp Med. 1995 Mar 1;181(3):1133-44
7532677
J Clin Immunol. 1986 Sep;6(5):363-72
2429979
Diabetes. 2007 Jan;56(1):177-85
17192480
Biotechniques. 1995 May;18(5):870-7
7619493
Adv Exp Med Biol. 1998;452:13-8
9889954
Lancet. 1977 May 14;1(8020):1025-7
67485
J Immunol Methods. 1998 Apr 1;213(1):87-97
9671127
J Clin Endocrinol Metab. 2000 Jan;85(1):76-80
10634367
Trends Mol Med. 2008 Apr;14(4):179-89
18353724
Autoimmunity. 2002 Feb;35(1):1-14
11908701
Nat Rev Immunol. 2003 Apr;3(4):304-16
12669021
Eur J Immunol. 2005 Aug;35(8):2452-8
15997468
J Immunol. 2008 Feb 1;180(3):1729-36
18209070
Immunol Today. 1997 Nov;18(11):538-42
9386350
Diabetologia. 1987 Dec;30(12):907-11
3436487
J Immunol. 2008 Apr 1;180(7):4679-86
18354191
J Exp Med. 2005 Oct 17;202(8):1075-85
16230475
Diabetologia. 1984 Jul;27 Suppl:102-5
6237011
Br Med J (Clin Res Ed). 1986 Jul 26;293(6541):244
3089475
Diabetes. 1986 Feb;35(2):237-41
3510930
Clin Chem. 1995 May;41(5):687-92
7729046
Proc Natl Acad Sci U S A. 2006 Apr 4;103(14):5460-5
16567639
Clin Immunol. 2004 Sep;112(3):258-67
15308119
Diabetes Care. 1995 Dec;18(12):1557-65
8722051
Cell Mol Immunol. 2006 Aug;3(4):241-54
16978532
J Immunol. 2007 Oct 1;179(7):4492-502
17878345
Diabet Med. 1994 Apr;11(3):299-303
8033530
Exp Hematol. 2007 Mar;35(3):416-25
17309822
Diabetologia. 1986 Jun;29(6):352-7
3527835
Proc Natl Acad Sci U S A. 2005 Jun 28;102(26):9253-7
15961541
Diabetes. 1999 Jan;48(1):150-7
9892237
Nat Rev Immunol. 2003 May;3(5):413-25
12766763
Immunity. 2003 Jan;18(1):41-51
12530974
J Clin Invest. 1993 Jan;91(1):368-74
8423232
Annu Rev Immunol. 1999;17:875-904
10358776
Eur J Immunol. 2008 Nov;38(11):2942-5
18979513
Trends Immunol. 2005 Nov;26(11):613-8
16118064
J Exp Med. 1994 Aug 1;180(2):537-43
8046332
Nat Rev Immunol. 2005 Mar;5(3):201-14
15719024
Immunol Res. 1998;17(3):303-12
9638474
J Immunol. 2001 Aug 1;167(3):1245-53
11466340
Diabetes Res Clin Pract. 1994 Feb;23(1):37-42
7516851
Immunobiology. 1990 Jun;180(4-5):431-40
2204602
Diabetologia. 1994 Apr;37(4):344-50
8063033
Nat Immunol. 2008 May;9(5):503-10
18425107
J Immunol. 2006 Feb 1;176(3):1582-7
16424187
Lancet. 1997 Nov 1;350(9087):1288-93
9357409
Diabetes Care. 1996 Aug;19(8):795-800
8842593